Catalyst Pharmaceuticals Q4 Adj. EPS $0.53 Beats $0.26 Estimate, Sales $110.57M Beat $106.12M Estimate
Portfolio Pulse from Benzinga Newsdesk
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported Q4 adjusted EPS of $0.53, surpassing the $0.26 estimate, and sales of $110.57M, exceeding the $106.12M estimate. This represents a significant increase in both earnings and sales compared to the same period last year.
February 29, 2024 | 7:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalyst Pharmaceuticals reported a strong Q4 with adjusted EPS of $0.53 and sales of $110.57M, both surpassing estimates and showing significant year-over-year growth.
The substantial beat on both earnings and sales estimates, coupled with the impressive year-over-year growth, is likely to positively impact investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100